There is only one combination of facts that makes it advisable for a company to repurchase its shares: First, the company has available funds -- cash plus sensible borrowing capacity -- beyond the near-term needs of the business and, second, finds its stock selling in the market below its intrinsic value, conservatively calculated.
-- Warren Buffett, 2000�
Investors love share buybacks. When a company buys shares of its own stock and retires them, it leaves fewer shares outstanding. This boosts earnings per share, because the company's net income is spread over fewer shares. Additionally, the buyback program tilts the supply demand balance for the stock in favor of sellers, which can push the share price higher.
Warren Buffett believes that share buybacks make sense only when two key conditions are fulfilled.
However, buybacks don't always make sense. Investing legend and Berkshire Hathaway CEO Warren Buffett has said that two conditions must be fulfilled for share buybacks to be a good use of capital. The company must have excess cash and borrowing ability to fund the buyback, and the stock needs to be clearly undervalued.
Top 10 Electric Utility Stocks To Invest In 2015: Derma Sciences Inc.(DSCI)
Derma Sciences, Inc. operates as a medical technology company. The company provides advanced wound care products, including Medihoney dressings that are used for the management of non-chronic and hard-to-heal wounds, such as chronic ulcers, burns, and post-operative wounds; Bioguard dressings that are used for prophylactic use in the prevention of hospital or community acquired infections through wound sites; Algicell Ag, antimicrobial dressings; Xtrasorb dressings that convert fluid within the dressings to a gel and lock the exudates into the dressings; TCC-EZ, a dressing system for the management of diabetic foot ulcers; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and Dermagran products. It also offers traditional wound care products, such as of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages, and other compression devices, as well as a dhesive bandages and related first aid products. In addition, the company provides pharmaceutical wound care products, including DSC127, an angiotensin analog for use in wound healing and scar reduction. It markets wound closure strips, nasal tube and catheter fasteners, barrier creams and ointments, antibacterial cleansing foams and sprays, shampoos and body washes, hand sanitizers, bath additives, body oils, and moisturizers to doctors, clinics, nursing homes, hospitals, home healthcare agencies, and other institutions. The company sells its products to health care providers, such as wound care centers, extended care facilities, acute care facilities, home health care agencies, and physicians? offices through direct sales representatives in the United States, Canada, and the United Kingdom; retail channels; manufacturers? representatives and independent distributors in international markets. Derma Sciences, Inc. was founded in 1984 and is headquartered in Princeton, New Jersey.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Derma Sciences (Nasdaq: DSCI ) , whose recent revenue and earnings are plotted below. - [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Derma Sciences (Nasdaq: DSCI ) , whose recent revenue and earnings are plotted below.
Top 10 High Tech Companies To Own For 2014: Octagon 88 Resources Inc (OCTX)
Octagon 88 Resources, Inc., incorporated on June 9, 2008, is a development-stage oil and gas company. The Company has acquired light and conventional heavy oil assets in Northern Alberta. On Jan 22, 2013, the Company launched the Conventional Oil Production Division by entering into a purchase agreement to acquire its share in the Red Earth Area, which consists of four contiguous sections of P&NG leases, a ( 40 API) Keg River formation with P3 reserves of 1.2 Mill barrels light sweet crude oil recoverable.
On December 24, 2012, the Company acquired a 22% interest of CEC North Star Energy Ltd. (North Star). On January 23, 2013, the Company acquired a 10% interest in North Star.
Advisors' Opinion:- [By Jonathan Yates]
It will also be bullish for publicly traded companies in each sector, ranging from prominent blue chips like Exxon Mobil (NYSE: XOM) and Goldcorp (NYSE: GG) to promising small caps like Octagon 88 (OTC: OCTX) and Wishbone Gold PLC (OTC: WISHY).
- [By Jonathan Yates]
There has been a great deal of concern about the United States suffering from a "lost generation" as Japan has now for several. For investors in oil, this has certainly not been the case: A recent article in The Wall Street Journal noted that oil has risen 310% (Brent Crude) over the last decade. The future looks equally promising for investments in the sector such as ConocoPhillips (NYSE: COP), Suncor Energy (NYSE: SU), Americas Petrogas (BOE.V), and Octagon 88 (OTCBB: OCTX).
- [By Jonathan Yates]
For investors looking for a play, small cap firms operating in the oil and natural gas sector in Canada, such as Octagon 88 (OTC: OCTX), Americas Petrogas (OTC: APEOF), and Connacher Oil and Gas (OTC: CLLZF) could draw attention.
- [By Jonathan Yates]
"Octagon 88 has received confirmation of 1.6 billion billion barrels PIIP," was the headline for the press release dated September 11, 2013. Needless to say, Octagon 88 (OTCBB: OCTX), a small cap oil and natural gas exploration based in Switzerland with assets in the oil-rich Alberta province of Canada, has soared on that and other bullish news. From early July, the stock price for Octagon 88 just about doubled.
Top 10 High Tech Companies To Own For 2014: Synutra International Inc.(SYUT)
Synutra International, Inc., through its subsidiaries, engages in the production, marketing, and distribution of dairy based nutritional products primarily in the People?s Republic of China. The company offers powdered infant and adult formula products for adults and children under the Super, U-Smart, My Angel, Mingshan, and Helanruniu brand names; prepared baby food for babies and children under the Huiliduo brand name; and nutritional ingredients and supplements, such as chondroitin sulfate, microencapsulated Docosahexanoic Acid, and Arachidonic Acid. It also sells milk powder, whey protein, and raw milk to industrial customers. The company markets its products under Shengyuan or Synutra brands. It sells its products through sales and distribution network covering 30 provinces and provincial-level municipalities in China. Synutra International, Inc. is headquartered in Rockville, Maryland.
Advisors' Opinion:- [By Seth Jayson]
Synutra International (Nasdaq: SYUT ) reported earnings on June 13. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q4), Synutra International missed estimates on revenues and beat expectations on earnings per share.
Top 10 High Tech Companies To Own For 2014: Ashland Inc. (ASH)
Ashland Inc. operates as a specialty chemicals company in the United States and internationally. Its Ashland Aqualon Functional Ingredients segment produces cellulose ethers; and specialty additives and functional ingredients. Its products offer functionality, such as thickening and rheology control; water retention; adhesive strength; binding power; film formation; protective colloid, suspending, and emulsifying action; foam control; and pH stability. The company?s Ashland Hercules Water Technologies segment manufactures papermaking chemicals and supplies specialty chemicals. It offers sizing agents, wet/dry strength additives, and crepe and release additives for tissue manufacturing; and deposit control agents, defoamers, biocides, and other process additives. This segment also provides specialized chemicals and consulting services for the utility water treatment; and performance-based feed and control systems; and monitoring devices and remote system surveillance. Its A shland Performance Materials segment manufactures and supplies specialty chemicals and customized services to the building and construction, transportation, metal casting, packaging and converting, and marine markets. It also offers unsaturated polyester and vinyl ester resins, and gelcoats; adhesives and specialty resins; and metal casting consumables and design services. The company?s Ashland Consumer Markets segment produces and markets packaged automotive lubricants, chemicals, appearance products, antifreeze, and filters to the private passenger car, light truck, and heavy duty markets. It also operates a quick-lube franchise under the name of Valvoline Instant Oil Change. The company was founded in 1918 and is headquartered in Covington, Kentucky.
Advisors' Opinion:- [By Shauna O'Brien]
Jefferies reported on Thursday that it has cut its rating on chemical company Ashland Inc. (ASH).
The firm has downgraded ASH from “Buy” to “Hold,” and has lowered the company’s price target from $104 to $97. This price target suggests a 9% upside from the stock’s current price of $88.47.
Analyst Laurence Alexander commented: “Investor confidence in the asset shuffling thesis may not withstand 2-3 more rounds of downward revisions to EPS and FCF forecasts for 2014E-2016E.”
“Pension headwinds, incentive comp, Valvoline marketing expenses, sluggish end markets: in our view, it all adds up, and makes further multiple expansion more difficult.”
Looking ahead, the firm has reduced estimates for the fourth quarter from $1.70 to $1.59 per share. For FY2013, earnings estimates have been lowered from $6.25 to $6.15 per share. FY2014 estimates have been cut from $7.45 to $6.75 per share.
Ashland shares were mostly flat during pre-market trading Thursday. The stock is up 10% YTD
- [By Seth Jayson]
Margins matter. The more Ashland (NYSE: ASH ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong Ashland's competitive position could be.
Top 10 High Tech Companies To Own For 2014: RLJ Lodging Trust(RLJ)
RLJ Lodging Trust is an independent equity real estate investment trust. The firm also manages real estate funds. It invests in the real estate markets of the United States. The firm primarily invests in premium-branded, focused service, and compact full-service hotels. RLJ Lodging Trust was launched in 2000 and is domiciled in Bethesda, Maryland.
Advisors' Opinion:- [By Markus Aarnio]
American Hotel Income Properties' competitors include Hospitality Properties Trust (HPT), RLJ Lodging Trust (RLJ), and Hersha Hospitality Trust (HT).
Top 10 High Tech Companies To Own For 2014: Vanguard Reit Etf (VNQ)
Vanguard REIT ETF (the Fund), formerly known as Vanguard REIT VIPERs, is an exchange-traded share class of Vanguard REIT Index Fund. The Fund seeks to provide a high level of income and moderate long-term capital appreciation by tracking the performance of an index that measures the performance of publicly traded equity real estate investment trusts (REITs). Vanguard REIT ETF employs a passive management or indexing investment approach designed to track the performance of the MSCI US REIT Index (the Index), an index of United States property trusts that covers about two-thirds of the value of the entire United States REIT market.
Vanguard REIT ETF normally invests approximately 98% of assets in stocks issued by equity REITs. The Fund invests in the stocks that make up the Index, and the remaining assets are allocated to cash investments.
Advisors' Opinion:- [By Dan Caplinger]
3. Real-estate investment trusts
Rate-sensitive REITs took another big hit over the week, with the Vanguard REIT ETF (NYSEMKT: VNQ ) dropping more than 5%. Leveraged mortgage REITs saw even worse losses, with Annaly Capital (NYSE: NLY ) falling more than 7% and American Capital Agency (NASDAQ: AGNC ) seeing 8% declines. - [By Howard Gold]
In May, I said real estate investment trusts (REITs) ��ave outperformed the S&P 500 for 11 of the last 16 quarters��and so ��'d be inclined to take at least some profits.��That column ran pretty close to REITs' all-time high and the Vanguard REIT Index ETF (VNQ) has lost 11% of its value.
- [By Bill Stoller]
After a banner 2013, the overall market has had a challenging start to 2014. However, these four companies have been crushing it: Alexander Real Estate (NYSE: ARE ) , BioMed Realty Trust (NYSE: BMR ) , CommonWealth REIT (NYSE: CWH ) , and Sun Communities (NYSE: SUI ) early on in 2014 vs. the S&P 500. Their relative out-performance can also be seen when compared to the Vanguard REIT Index ETF (NYSEMKT: VNQ ) a good yardstick to measure sector performance.
Top 10 High Tech Companies To Own For 2014: Roche Holding AG (RHHBY)
Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. The Company belongs to the Roche Group that operates through numerous subsidiaries and associated companies located around the world. The Company�� products and services cover every stage of the healthcare process, from identifying disease susceptibilities and testing for disease in at-risk populations to prevention, diagnosis, therapy and treatment monitoring. Roche operates through two divisions: Pharmaceuticals and Diagnostics. Within the Pharmaceuticals Division there are three sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. The Company�� Diagnostics Division includes five sub-divisions: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. Its activities are structured into six geographical segments: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan. In March 2009, the Company completed the acquisition of Genentech, Inc. In March 2010, the Company acquired assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow.
During the year ended December 31, 2008, the Company Pharmaceuticals Division marketing gained approvals for its rheumatoid arthritis medicine Actemra/RoActemra in Japan, Switzerland and the European Union. In 2008, the division initiated 12 new phase III projects in, including clinical trials of the compounds pertuzumab, for breast cancer; taspoglutide, for type two diabetes, and dalcetrapib, for cardiovascular risk reduction. As of December 31, 2008, the Pharmaceuticals Division filed 11 major new marketing applications and gained 13 major regulatory approvals. At the beginning of 2009, the division�� research and development pipeline comprised 120 clinical projects, including 62 new molecular entities (NMEs) and 58 additional indications. Forty NMEs are in phase I, 16 in phase II and six in phase III or f! iled for regulatory review.
In 2008, Roche Pharmaceuticals signed a total of 57 new agreements including seven product transactions and 43 research and technology collaborations. In May 2008, Roche acquired Piramed Limited, a UK company with therapeutic research programmes targeting the PI3-kinase pathway in oncology and inflammatory disease. In June 2008, signed licensing agreement with ThromboGenics and BioInvent for their jointly developed anticancer agent TB-403 (R7334). In September, 2008, the Company acquired Mirus Bio Corporation active in the field of ribonucleic acid interference (RNAi) delivery and completed the acquisition of ARIUS Research Inc., which has a antibody platform that identifies and selects antibodies based on their functional ability to affect disease. S Research Inc. In January 2009, Roche acquired Memory Pharmaceuticals, which develops drug candidates for the treatment of debilitating central nervous system disorders such as Alzheimer�� disease and schizophrenia.
Pharmaceuticals
Within Pharmaceuticals division, the Company is engaged in the provision of drugs the areas of oncology, anemia, cardiovascular diseases, central nervous system, infectious diseases, inflammatory and autoimmune diseases, metabolic disorders, cancer, transplantation and virology. The products offered by Roche�� Pharmaceuticals division include MabThera/Rituxan, Herceptin, Avastin, Tamiflu, CellCept, NeoRecormon, Epogin, Pegasys, Tarceva, Xeloda, Bonviva, Boniva, Lucentis, Tamiflu, Xolair, Valcyte, Cymevene, Xenical, Pulmozyme, Nutropin, Neutrogin, Rocephin, Activase, TNKase and Madopar. The products offered by the Pharmaceuticals division are sold in seven geographic regions: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan.
Diagnostics
Roche�� Diagnostics Division is a supplier of in vitro diagnostics (IVDs). Its products are used to test body fluids a! nd tissue! samples to obtain information for the purpose of preventing, diagnosing, treating and monitoring disease. The Company has business areas five within the diagnostics division: Professional Diagnostics, Diabetes Care, Tissue Diagnostics, Molecular Diagnostics and Applied Science. Roche�� Diagnostics division provides IVD services, including centralized laboratory testing and point-of-care diagnostics to molecular diagnostics and diabetes self management. In addition, it supplies research tools to life scientists.
Roche Professional Diagnostics supplies instrument systems, tests, software and services. It provides point-of-care testing products to support clinical decision-making close to the patient, in doctors��offices, emergency rooms and other primary and specialty care settings. Twelve Serum Work Area assays were rolled out during the year ended December 31, 2008, across Europe and in other markets. New assays included the Elecsys anti-TSH receptor antibody assay for the diagnosis of Graves��disease the Elecsys anti-CCP antibody assay, a test to aid the diagnosis of rheumatoid arthritis, and the Roche Cystatin C clinical chemistry test for early detection of impaired kidney function, among others. Roche Diabetes Care�� products portfolio covers the entire diabetes self-management spectrum, from glucose monitoring to insulin delivery, as well as monitoring systems with integrated lancets and test strips software for storing and analyzing data. Roche Tissue Diagnostics develops and manufactures medical diagnostic instruments and reagent systems that provide automation technology for use in the diagnosis and prognosis of cancer and infectious disease. In 2008 Roche Tissue Diagnostics launched ofhe Bench- Mark Ultra, a system that performs immunohistochemistry and in situ hybridisation testing simultaneously on a single continuous and random access platform. Roche Molecular Diagnostics develops and commercializes diagnostic and blood screening platforms and tests based on Roche�� ! real-time! polymerase chain reaction (PCR) technology. Applied Science business area supplies a specific reagents and test kits for use in life sciences encompassing biology, biotechnology ,medical research, as well as disease areas like cancer and virology. Applied Science�� business area product portfolio includes such sequencing systems as LightCycler 480, LightCycler 480 II, GS FLX Titanium. In addition, Applied Science offers xCELLigence cell analyzer.
Advisors' Opinion:- [By Sean Williams]
Dendreon's likely partner
While it's purely speculation on my part, I believe the most likely marketing partner would be one of Europe's premier cancer-fighting companies, Roche (NASDAQOTH: RHHBY ) . - [By Michael Robinson]
In December, Prothena signed a deal with drug giant Roche Holding AG (RHHBY) to develop and commercialize Parkinson's treatments that could be worth up to $600 million.
- [By Ben Levisohn]
Shares of Regeneron have jumped 3.5% to $316.39–and the S&P 500′s best performer today. Novartis (NVS), which makes Lucentis, has dipped 0.5% to $76.73, while Roche (RHHBY), which makes Avastin, has gained 0.2% to $67.54. Vertex Pharmaceuticals (VRTX), meanwhile, has gained 0.9% to $76.77, making it the 10th best perform in the S&P 500.
No comments:
Post a Comment